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850Objective: Parenchymal pulmonary nodules located in proximity to the mediastinum, vertebral column, major
vessels, or behind the heart can be technically challenging and dangerous to biopsy using traditional
image-guided techniques. Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) can be used to
access some of these difficult to reach lesions. The purpose of the present study was to report our experience
with this technique in a consecutive cohort of selected patients.
Methods: This was a retrospective cohort study. Eligible patients were identified from a prospective database.
A transesophageal approach under real-time EUS guidance was performed using a 22-gauge needle. All patients
underwent postprocedural chest radiography and were followed up at 30 days.
Results: During a 31-month period, 55 patients underwent EUS-guided lung biopsy. Confirmatory visual
correlation of nodule localization within the lung parenchyma between computed tomography and EUS was
possible in 100% of cases. The lung nodule distribution was 41.5% right upper lung, 18.9% right lower
lung, 28.3% left upper lung, and 11.3% left lower lung. Histologic and cytologic sampling was adequate in
52 of the 55 procedures (94.5%). In all patients with adequate biopsy sampling, accurate pathocytologic
diagnoses of the target parenchymal nodules were obtained. The accuracy and sensitivity of EUS-FNA were
both 94.5% and consistent with the diagnosis on pathologic resection or clinical progression of disease,
or both. No morbidity resulted from the procedure nor was observed at 30 days.
Conclusions: EUS-FNA of parenchymal pulmonary nodules is safe and accurate and allows for biopsy
of perimediastinal lung lesions not attainable using traditional techniques. (J Thorac Cardiovasc Surg
2014;148:850-5)Lung cancer is the leading cause of cancer death in the
United States, with an estimated incidence of 224,210
new cases in 2014.1 Patients with non–small cell lung
cancer (NSCLC) typically present with a lung nodule or
mass that might or might not be symptomatic. Recently,
the National Lung Screening Trial has shown that screening
with low-dose computed tomography (CT) is efficacious
and associated with reduced mortality.2 Thus, lung cancer
screening is expected to increase the number of patients
presenting for diagnostic evaluation of a pulmonary nodule
or mass. In certain patients, tissue for pathologic analysis is
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The Journal of Thoracic and Cardiovascular SurgMany options exist for obtaining samples from the
parenchymal lung nodule for pathologic analysis, including
transthoracic image-guided needle aspiration (TTNA),
transbronchial biopsy (TBNA), endobronchial ultrasound-
guided biopsy, navigational bronchoscopic guidance
biopsy, and thoracoscopic or open lung biopsy. Paren-
chymal pulmonary nodules located in proximity to the
mediastinum, in front of the vertebral column, in proximity
to major vessels, or behind the heart can be technically
challenging and dangerous to biopsy using traditional
image-guided techniques. Endoscopic ultrasound-guided
fine needle aspiration (EUS-FNA) has become common
for diagnosing mediastinal lymph nodes in lung cancer;
however, its utility in biopsying parenchymal pulmonary
nodules is not known. The present study reports on the
largest reported experience with transesophageal needle
aspiration of lung nodules using real-time EUS guidance.
METHODS
The study was a retrospective cohort study using a prospective
interventional endoscopy research database. Patients presented to the
CHUM Endoscopic Tracheobronchial and Oesophageal Center in the
Division of Thoracic Surgery at the Centre Hospitalier de l’Universite de
Montreal during a 31-month period with a lung mass suspicious for either
a primary or secondary neoplasm of the lung. These patients had undergone
attempts at lung biopsy using traditional techniques that were unsuccessful
at obtaining a diagnosis, were not eligible for traditional lung noduleery c September 2014
Abbreviations and Acronyms
CT ¼ computed tomography
EUS ¼ endoscopic ultrasound
EUS-FNA ¼ endoscopic ultrasound-guided fine
needle aspiration
NSCLC ¼ non–small cell lung cancer
TBNA ¼ transbronchial biopsy
TTNA ¼ transthoracic image-guided needle
aspiration
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Sbiopsy owing to anatomy or nodule location, or traditional techniques for
lung nodule biopsy were thought to be too dangerous to attempt. All
patients undergoing transesophageal biopsy of an intraparenchymal lung
lesion using real-time EUS during the study period were included. The
aim of the present study was to evaluate the rate of successful tissue
sampling, the accuracy of the diagnostic test, and safety.
The institutional review board at the Research Center of the Centre
Hospitalier de l’Universite de Montreal approved the electronic
prospective database used for the present study and approved this trial.
Patient consent was obtained for entry into the prospective database; the
institutional review board granted a waiver for individual patient consent
for the present retrospective review.
All patients had undergone a standard diagnostic evaluation of their lung
lesion with a history, physical examination, and standard imaging studies,
including CTof the chest and upper abdomen with intravenous contrast and
5-mm cuts. Positron emission tomography scans were performed in
patients with a suspicion for NSCLC. Positron emission tomography was
performed from the skull base to the mid-thigh level. The maximum
standardized uptake value of the primary and each suspicious lymph
node station was determined. The clinical TNM stage was recorded. In
certain patients, a biopsy was desirable for treatment planning. Such
patients included those with a history of a treated malignancy, multiple
comorbidities who were at high risk for lung resection, and those
considered for stereotactic body radiotherapy. In addition, patients who
met the criteria for invasive mediastinal staging according to the most
recent American College of Chest Physician’s guidelines were included
if an EUS-guided lung biopsy had been undertaken in conjunction with
their staging procedure.3 Patients with an endobronchial component were
excluded, because biopsy of the lesion was undertaken transbronchially.
The data from all patients were reviewed for the possibility of a
transthoracic or transbronchial needle biopsy by radiologists, pulmonolo-
gists, and thoracic surgeons. For all patients, these procedures had either
been attempted and found to be nondiagnostic or were not deemed safe
owing to the anatomy.
EUS Technique
A convex probe EUS scope was used to perform real-time transesopha-
geal needle biopsy (EUS Linear Scope, GF-UC140P-AL5; Olympus
America Inc, Center Valley, Pa). A dedicated 22-gauge needle (ECHO-1-
22; Cook Medical Ireland Ltd, Limerick, Ireland) was used to perform
all EUS needle biopsy procedures under real-time ultrasound guidance.
No core needle biopsies were used. No transvascular biopsies were
performed. The smears were air dried and fixed on a slide. Additional
samples were preserved in Cytolyt solution for cell block preparation.
We performed as many passes as needed until satisfied with the gross
appearance of the specimen. On average, this required 2 to 4 passes. Rapid
on-site evaluation by a cytopathologist was not performed. An upright
chest radiograph was obtained in the recovery area after the procedure to
rule out iatrogenic pneumothorax. Conscious sedation was used for all
procedures.The Journal of Thoracic and CaDefinitions and Statistical Methods
A negative result was defined as a lung nodule labeled as benign by EUS
and an adequate needle aspiration that identified the absence of tumor cells.
A false-negative result was defined as the subsequent identification of
malignancy, by either resection or biopsy using another method, within a
mass deemed negative for malignancy by EUS-FNA. The efficacies
(accuracy, sensitivity, and negative predictive value) of these tests were
computed using standard definitions.
RESULTS
From October 2010 to May 2013, 1165 patients
underwent combined endosonographic evaluation of
biopsy-proven lung cancer or highly suspicious pulmonary
lesions using combined endobronchial and endoesophageal
ultrasound. Of the 1165 patients, 55 underwent planned
transesophageal real-time ultrasound-guided biopsy of a
suspicious lung lesion. The demographic data for these
patients are listed in Table 1. The remaining 1110 patients
did not undergo transesophageal lung biopsy. Therefore,
no patient had transesophageal biopsy planned that was
not attempted owing to anatomic constraints. All
patients underwent CT of the chest and upper abdomen
with 5-mm collimated cuts.
In all patients, the lesion was visualized using ultrasonog-
raphy and correlated with the suspicious lesion on the CT
scan. The distribution of the location for all the lesions is
listed in Table 1, with the right and left upper lobes the
most common location for the lesions in the present series.
Unsurprisingly, all the lesions were located within the inner
third of the thoracic cavity, making access by way of the
esophagus feasible.
A diagnostic sample was obtained from 52 of the 55
patients, for a diagnostic yield of 94.5%. In all patients
with adequate biopsy sampling, an accurate pathocytologic
diagnosis of the target parenchymal nodules was obtained.
The accuracy and sensitivity of EUS-FNA were both
94.5% and was consistent with the diagnosis on pathologic
resection or clinical disease progression, or both. The
distribution of the diagnoses is listed in Table 2. NSCLC
was the most common diagnosis in the present series. In
all 3 patients with a nondiagnostic sample, additional
pathologic analysis was obtained in the form of anatomic
lung resection (2 pneumonectomy and 1 lobectomy). In
all 3 patients, the final pathologic examination confirmed
the presence of NSCLC. No negative results were found,
and all diagnostic results yielded a diagnosis of malignancy.
Therefore, the prevalence of malignant disease in the
present series was 100%.
The nodule volume on EUS compared with that on CT
scans had a Pearson product-moment correlation coefficient
of 0.954 and Student t test result of 0.044. The diagnostic
accuracy was unaffected by tumor phenotype between
NSCLC and small cell lung cancer.
No patients had either pneumothorax or new pleural effu-
sion on the postprocedural chest radiograph. No immediaterdiovascular Surgery c Volume 148, Number 3 851
TABLE 1. Demographic and preprocedure data
Variable Value
Age (y)
Mean 63
Range 39-83
Female sex (n) 31 (56)
Largest dimension on CT (mm)
Mean 49.3
Range 8-110
<15 2 (3.6)
16-30 10 (18)
>30 43 (78)
Distance between lesion and esophagus (mm)
Mean 25
Range 0-46
Patients who underwent PET (%) 56
Location
Right upper lobe 23 (42)
Right lower lobe 10 (18)
Left upper lobe 16 (29)
Left lower lobe 6 (11)
Data presented as n (%), unless otherwise noted. CT, Computed tomography;
PET, positron emission tomography.
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procedure occurred. All patients were discharged on the
same day of their procedure. No readmissions were required
for any procedure-related complications. No patients
reported dysphagia or odynophagia on long-term follow-up.DISCUSSION
With the advent of lung cancer screening, the incidence
of lung nodules and masses requiring evaluation has
increased. In the present study, we have demonstrated the
utility of transesophageal ultrasound-guided lung biopsy
in establishing a cytopathologic diagnosis in a much
selected group of patients requiring biopsy for whom
anatomic constraints make traditional methods unfeasible.
We report a diagnostic yield of>90%, albeit in a selected
group of patients with a disease prevalence of 100%.
Regardless of stage, the goal of the initial evaluation is to
confirm the diagnosis and establish the disease stage using
tests with the greatest accuracy and lowest associated
morbidity.4 The lung nodule biopsy options include TTNA,
TBNA, endobronchial ultrasound-guided biopsy, naviga-
tional bronchoscopic guidance biopsy, and thoracoscopicTABLE 2. Results of needle biopsy
Diagnosis Patients (n)
Non–small cell lung cancer 44 (80)
Small cell lung cancer 4 (7.3)
Metastatic neoplasm 4 (7.3)
Nondiagnostic sample 3 (5.5)
Data in parentheses are percentages.
852 The Journal of Thoracic and Cardiovascular Surgor open lung biopsy. The choice of technique is largely
dependent on the location of the lesion.
For peripheral lesions, TTNA has been reported to be safe
and efficacious and is the procedure of choice for biopsy of
lung lesions in this subset of patients. Geraghty and
colleagues5 reported their experience with TTNA in 846
patients, with a sensitivity of 91% and specificity of
99%. The incidence of pneumothorax in their series was
38%.5 This percentage was related partially to needle
size, and they concluded that the use of a coaxial 18-gauge
needle might reduce the incidence of this complication
without compromising the diagnostic accuracy.5 However,
studies on the efficacy of TTNA have been limited to reports
of peripheral lung lesion. Although few data have been
published regarding its role in central or hilar lesions, it
only seems natural that the test performance could be
compromised. For such central lesions, TBNA has been
the preferred approach. Multiple options exist, including
direct TBNA, brush cytology, bronchoalveolar lavage,
ultrasound-guided and radial probe endobronchial ultra-
sound, and, more recently, electromagnetic navigational
bronchoscopy. The reported sensitivity of TBNA in the
setting of a visible endobronchial abnormality has been
88%.6 However, that study included patients with an
endobronchial abnormality, whether a visible intraluminal
lesion or extrinsic compression of a bronchus. Baaklini
and colleagues7 examined the accuracy of TBNA tech-
niques in relation to the distance from a central bronchus.
They noted that the sensitivity of TBNA varied with the
distance from the hilum.7 The yield of bronchoscopy in
central, intermediate, and peripherally located lesions was
82%, 61%, and 53%, respectively. Thus, TBNA is
preferred for central, peribronchial lesions, especially if
an endobronchial component is found.
In certain cases, a suspicious lesion might not be easily
classified as a central or peripheral lesion. An example
would be the lesions in the patients whose scans are shown
in Figure 1. These lesions were located within the inner
third of the thoracic cavity, out of reach of TTNA in most
institutions. However, they were not in a peribronchial
location amenable to TBNA. These were peripheral lesions
located adjacent to the mediastinal surface of the lung, ideal
for transesophageal biopsy. This is not a novel technique,
and previous studies have reported the use of EUS for
biopsy of lung lesions. Aaraya and colleagues8 reported
on the use of transesophageal needle biopsy for the
molecular diagnosis of lung cancer. That study included
26 patients undergoing biopsy. Most of the patients
underwent biopsy of mediastinal lesions; however, 5
patients underwent biopsy of pulmonary nodules without
complications. The diagnostic yield was 100% for lung
cancer using combined transesophageal and bronchoscopic
techniques, with an additional diagnostic gain of 69% for
EUS and bronchoscopy compared with bronchoscopyery c September 2014
FIGURE 1. A, C, and E, Images of computed tomography scans and (B), (D), and (F), corresponding endoscopic ultrasound images. These were patients
who had undergone a failed attempt at transbronchial needle biopsy (patient 2) or were not candidates for either transbronchial or transthoracic needle biopsy
(patients 1 and 3) for anatomic reasons. Arrows indicate abnormality. CT, Computed tomography.
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demonstrated the efficacy of transesophageal EUS in the
diagnosis of lung lesions in 51 patients who had undergone
a nondiagnostic attempt using TTNA or TBNA. The
sensitivity, specificity, and negative predictive value of
combined transbronchial and transesophageal ultrasound
needle biopsy was 89.8%, 100%, and 20%, respectively.
Similar to our study, theirs was a highly selected group of
patients with a prevalence of malignancy of 97.5% and a
mean lesion size of 32.1 mm. Two additional reports have
been published of transesophageal EUS-guided lung biopsy
using a dedicated EUS scope. The first, by Annema and
colleagues,10 demonstrated a diagnostic yield of 97% in a
group of 32 patients. The second study, by Varadarajulu
and colleagues,11 reported on EUS-guided needle biopsy
of lung lesions after unsuccessful attempts at CT-guided
or bronchoscopic sampling to establish a tissue diagnosis.The Journal of Thoracic and CaThey demonstrated a 100% diagnostic yield in 18
patients.11
As we have demonstrated in our series, this technique is
safe and yields a diagnosis for 95% of cases. In the 3
patients in whom a diagnosis was not obtained, the result
was inconclusive, not falsely negative. This compares
very well to contemporary reports of the TTNA and
TBNA techniques. Furthermore, recent data have shown
that EUS mediastinal staging is at least as good as surgical
staging using mediastinoscopy.12,13 The addition of a
EUS-guided lung biopsy at the same time during combined
endosonographic staging seems logical. With a positive
result, this could eliminate the need for an additional
procedure such as TTNA. A theoretical risk exists of tumor
seeding along the needle track. It is difficult to comment on
such an incidence with the small number of patients and
limited long-term follow-up. Anecdotally, however, werdiovascular Surgery c Volume 148, Number 3 853
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needle track resulted in a change in stage or oncologic
outcome.
A comment should be made about the analysis of positive
results. The reference standard for pathologic diagnosis is
surgical resection of the nodule. If a patient underwent
resection, the positive biopsy result was confirmed by the
final pathologic examination. However, in this cohort,
surgical resection was not undertaken in all patients owing
to an advanced stage or medical inoperability. In patients
with advanced disease, disease progression was found at a
median follow-up of 5 months. The most difficult group
to treat was patients with early-stage tumors who were
medically inoperable. In all these patients, a positive result
by EUS was not confirmed and was assumed to be true.
The present study had several limitations. The most
obvious was that the present series was a retrospective
analysis with all the limitations inherent to such studies.
Furthermore, the prevalence of malignant disease in our
series was 100%. This was a highly selected group of pa-
tients with large tumors and significant fluorodeoxyglucose
avidity on positron emission tomography scans such that the
performance of any test was likely to be good. This raises 3
issues. The first is whether it is necessary to confirm such
masses with a biopsy because the pretest probability is
overwhelmingly in favor of malignancy. We believe that
biopsy is not necessary in cases that are resectable in
low-risk patients, for whom the overwhelming likelihood
is primary lung cancer. However, in patients with a high
risk for resection or patients for whom neoadjuvant or
definitive chemotherapy or radiotherapy is indicated, a
biopsy is desirable. Another group of patients who will
benefit from biopsy are those with a history of treated
extrathoracic malignancy, for whom the question will be a
metastatic lesion versus primary lung cancer. In these
patients, the treatment plans will diverge significantly, and
a biopsy will be helpful in planning care. The second issue
is related to the first, insofar as that the cohort represents a
highly selected group of patients with large tumors that
were centrally located with a prevalence of malignancy of
100%. Because this was our early experience, we selected
patients with a high probability of success. Thus, it is
difficult to define the role of EUS-guided lung biopsy for
smaller lesions. With more experience with the technique,
we hope that in the future we will publish our results with
smaller or more difficult to access lesions. The third issue
is how to define the role of EUS lung biopsy compared
with TTNA and TBNA. This is a difficult question to
answer, because our study was not a comparative study,
and TTNA or TBNA could certainly have performed well
in a subset of patients with a 100% disease prevalence.
Rather, EUS is a complimentary technique that can be
used to confirm disease in cases in which either TTNA or
TBNA is not feasible. The patients in the present study854 The Journal of Thoracic and Cardiovascular Surghad undergone nondiagnostic TTNA or TBNA or were
not candidates for TTNA or TBNA owing to the tumor
location or patient anatomy.CONCLUSIONS
We believe that our results have demonstrated the
feasibility and safety of EUS lung biopsy in patients with
primary and secondary lung malignancies requiring a tissue
diagnosis. At our institution, in cases in which a diagnosis is
required before treatment, percutaneous transthoracic and
transbronchial techniques remain the most common
methods of obtaining tissue from lung nodules. We use
EUS lung biopsy in selected patients in whom the lesion
is adjacent to the mediastinum but not located peribron-
chially, such that transbronchial techniques are applicable.
We have mainly used it in situations in which the
pretreatment biopsy results will alter treatment, such as
high-risk patients or patients with a history of a treated
extrathoracic malignancy, and to differentiate small cell
lung cancer from NSCLC. No complications developed in
the present small series.References
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SDiscussion
Dr Kenton J. Zehr (Baltimore, Md). How user dependent is
this technique? Do you think everybody can do this, or does this
require technical skill beyond the norm?
Dr Liberman. I would say that it depends on the size of the
nodule. For the 8-mm nodule, it might require more technical
savvy or experience. However, for the larger lesions, this is not
very complex. It is fast. It takes about 30 seconds to 1 minute.
Most of these procedures can be done with local sedation and
without general anesthesia as an outpatient procedure, and I would
say that anyone doing EUS for mediastinal lymph nodes can do
this without a lot of practice.
Dr Zehr. Do you think this approach for diagnosis will become
part of the guidelines?
Dr Liberman. I would say that in general we do not
recommend biopsying all lung nodules before surgery in low-risk
patients who have a high likelihood of malignancy. I think the use-
fulness of this procedure, which is similar to that for transthoracicThe Journal of Thoracic and Caneedle aspiration, is in the high-risk patient or a patient in whom
the diagnosis will change your surgical management.
Also, I would say that, as most people know, the complication
and pneumothorax rate of a TTNA under CT guidance ranges
from 10% to 20%, depending on which center and the severity
of the emphysema, and we have seen no pneumothorax, even in
high-risk patients with emphysema.
Dr Vinay Badhwar (Pittsburgh, Pa). The technology of
EUS-FNA is still in the process of development. Do you think
for distant lesions or lesions that are just beyond the scope,
additional technologic ultrasoundmodification should be required,
such as the use of 3-dimensional ultrasound?
Dr Liberman. It is a good question. Air is the enemy of
ultrasound, and ultrasonographers do not like air, and the lung is
full of air. So I think that makes it very, very hard.
As the lesions get further away from the mediastinum or from
your target, which is your EUS scope, it becomes more difficult
to see these lesions. Ultrasound technology on EUS compared
with endobronchial ultrasound has been around for almost 20
years now, and the technology is in its 10th or 12th generation.
Also, we are pretty good at seeing these lesions.
Again, I think as technology improves, it will become easier and
easier to use these devices. However, we see these nodules quite
well.rdiovascular Surgery c Volume 148, Number 3 855
